Why Most Medical Devices Take Too Long to Reach Hospitals in Brazil

There’s a moment every manufacturer entering Brazil looks forward to.

Regulatory approval’s granted.

After months—sometimes longer—the product’s officially authorized.

At that point, the expectation’s clear:

Now things should move.

But then something unexpected happens.

They don’t.

At least not at the pace most companies anticipate.

Weeks go by. Then months.

The product’s approved but not widely used.

And the question starts to surface:

What’s slowing things down?

The Assumption That Doesn’t Hold

Many manufacturers operate under a reasonable assumption:

If a product’s approved, hospitals should be able to adopt it.

From a regulatory standpoint, that’s true.

From a market perspective, it’s only part of the picture.

Because in Brazil, hospital adoption depends on a set of dynamics that sit outside the regulatory process.

And that’s where timelines tend to stretch.

Approval and Adoption Follow Different Logics

Regulatory approval’s a technical process.

Documentation’s reviewed. Requirements are met. Compliance’s verified.

Hospital adoption works differently.

It’s influenced by:

Clinical validation. Internal hospital processes. Budget constraints. Procurement structures. And often, existing supplier relationships.

Which means that even after approval, the product still needs to go through another layer of evaluation—this time inside the hospital.

The Internal Path Inside Hospitals

In many Brazilian hospitals, new technologies don’t go directly from approval to purchase.

They go through internal pathways that can include:

Clinical committees. Technical evaluations. Cost-benefit analysis. Pilot usage or physician validation.

These steps aren’t barriers.

They’re part of how hospitals manage risk and ensure quality of care.

But they do take time.

And if manufacturers aren’t prepared for this phase, progress slows down.

Distribution Alone Doesn’t Solve It

Another common expectation’s that once a distributor’s in place, adoption will follow.

Sometimes it does.

Often, it doesn’t.

Because distribution in Brazil’s not just about availability.

It’s about access.

A distributor may have reach—but that doesn’t automatically translate into:

Clinical engagement. Hospital relationships. Influence in procurement processes.

We’ve seen products with strong distributors still struggle to gain traction simply because the commercial approach wasn’t aligned with how hospitals actually adopt new technologies.

The Role of Physicians Is Bigger Than Expected

One of the most decisive factors in adoption’s often underestimated.

Physicians.

When doctors understand a technology, trust its outcomes, and see value in their practice, things move faster.

Conversations inside hospitals change.

Committees become more receptive.

Procurement gains context.

Without that clinical engagement, adoption can take significantly longer—even for high-quality products.

Timing’s Often Decided Before Approval

This is where things get interesting.

In many cases, the speed of adoption after approval’s determined by what happened before approval.

Were key hospitals already identified?
Were physicians engaged early?
Was the distribution strategy aligned with the product’s clinical pathway?
Was there a clear plan for post-approval market access?

When these elements are in place, adoption tends to move more smoothly.

When they’re not, companies find themselves building the structure after approval—which naturally takes more time.

The Gap Between Approval and Real Use

This gap’s where many manufacturers lose momentum.

Not because the product lacks value.

But because the path from regulatory clearance to hospital use wasn’t fully mapped.

Brazil’s not unique in this sense—but the scale and complexity of the system make this gap more visible.

And more impactful.

Shortening the Journey

Companies that reduce time to adoption tend to approach Brazil differently.

They don’t treat regulatory approval as a standalone milestone.

They treat it as one step within a broader market access strategy.

That includes:

Planning hospital engagement early. Aligning distribution with clinical realities. Preparing for procurement dynamics. And building relationships before the product’s even approved.

It’s not about accelerating one step.

It’s about connecting all of them.

Brazil Rewards Those Who Prepare Beyond Approval

Brazil offers significant opportunities for medical device manufacturers.

But it also requires a broader view of what “market entry” actually means.

Approval gets you into the system.

Adoption gets you into the hospital.

And the companies that understand the difference are usually the ones that move faster—not slower—once approval’s granted.

A Different Question to Ask

Instead of asking:

“How long does approval take?”

A more useful question might be:

“How long will it take for our product to be used inside hospitals—and what needs to happen to get there?”

That shift changes the way companies prepare.

And often, it shortens the journey in ways that regulation alone cannot.

Find out more about BPO in RA!  

*Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br